FUNDAMENTALS · Fundamentals · US Healthcare

Odyssey Therapeutics (ODTX) Fundamentals 2026 — Revenue Analysis | SniperIQ

Odyssey Therapeutics (ODTX) is a US-listed Healthcare company in Biotechnology with a market capitalization of $550M, trading at

8.21 on the NASDAQ. This SniperIQ fundamentals page covers Odyssey Therapeutics's valuation, profitability (net margin -4994.9%), revenue (
M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$550M
Net Margin-4994.9%
Revenue (FY25)
M

Full research coverage

Frequently Asked Questions

What is Odyssey Therapeutics's market cap?

Odyssey Therapeutics (ODTX) has a market capitalization of approximately $550M, trading at

8.21 on the NASDAQ. Market cap moves with the live share price.

How profitable is Odyssey Therapeutics?

Odyssey Therapeutics runs a net profit margin of -4994.9%, a gross margin of 100.0%, and an operating margin of -5415.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Odyssey Therapeutics generate?

Odyssey Therapeutics reported revenue of

M for fiscal year 2025, with net income of -
49M and earnings per share (EPS) of -5.39. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Odyssey Therapeutics pay a dividend?

Odyssey Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Odyssey Therapeutics financially healthy?

Odyssey Therapeutics carries a debt-to-equity ratio of -0.06x and a current ratio of 7.20x, with a market beta of 0.00. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Odyssey Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Odyssey Therapeutics (ODTX) the key facts are: market cap $550M, revenue

M, 52-week range 15.1-20.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Odyssey Therapeutics's full fundamentals live

Get Odyssey Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.